Molecular Partners
From Wikipedia, the free encyclopedia
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland.[2] The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins,[3] with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.[1]
Quick Facts Company type, Traded as ...
![]() | |
Company type | Public |
---|---|
SIX: MOLN Nasdaq: MOLN | |
Industry | Biotechnology |
Founded | 2004; 20 years ago (2004) |
Headquarters | Schlieren, canton of Zürich, Switzerland |
Key people |
|
Total assets | CHF 145.6 million (Mar. 31, 2021)[1] |
Number of employees | 152 FTE (Mar. 31, 2021) [1] |
Website | molecularpartners |
Close